Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Frequently asked questions
What sector does Belite Bio Inc ADR (BLTE) operate in?
Belite Bio Inc ADR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Belite Bio Inc ADR (BLTE) current stock price?
As of the latest data, Belite Bio Inc ADR stock price is $163.05, with a previous close of $160.67. Belite Bio Inc ADR gained $2.38 in the last trading session, representing a 1.48% increase.
What is Belite Bio Inc ADR (BLTE) current market capitalization?
Belite Bio Inc ADR market cap is approximately 6.54 billion.
What is Belite Bio Inc ADR (BLTE) Earnings Per Share (EPS)?
The trailing EPS is -$2.54, and the forward EPS is $0.94.
What is Belite Bio Inc ADR (BLTE) EBITDA?
Belite Bio Inc ADR EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -26.94 million.
Does Belite Bio Inc ADR (BLTE) pay dividends?
No. Belite Bio Inc ADR does not pay a dividend.
When is Belite Bio Inc ADR (BLTE) next earnings report?
Belite Bio Inc ADR is expected to release its next earnings report on June 30, 2026.
What is Belite Bio Inc ADR (BLTE) beta (volatility) score?
Belite Bio Inc ADR has a beta of -1.234, indicating lower volatility than the overall market.
